[Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University

• Publication date

  2018-06-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3969/J.ISSN.1673-4254.2018.06.13PMID 29997096PMCID PMC6765720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

  2018cited by this paper
• Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.

  2018cited by this paper
• Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

  2017cited by this paper
• Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up‐regulation of IRF1

  2017cited by this paper
• Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.

  2017cited by this paper
• Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer

  2017cited by this paper
• The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

  2017cited by this paper
• Chromogranin A and neurone‐specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration‐resistant prostate cancer undergoing abiraterone therapy

  2017cited by this paper
• Drug discovery in advanced prostate cancer: translating biology into therapy

  2016cited by this paper
• Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals

  2015cited by this paper
• Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population

  2015cited by this paper
• Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.

  2014cited by this paper
• The role of inflammation in prostate cancer.

  2014cited by this paper
• Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.

  2014cited by this paper
• Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

  2013cited by this paper
• Neuroendocrine‐derived peptides promote prostate cancer cell survival through activation of IGF‐1R signaling

  2013cited by this paper
• Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.

  2013cited by this paper
• Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation

  2013cited by this paper
• In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147

  2012cited by this paper
• Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

  2012cited by this paper
• Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.

  2011cited by this paper
• Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer

  2009cited by this paper
• Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.

  2009cited by this paper
• Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside

  2007cited by this paper
• Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

  2007cited by this paper
• Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells.

  2007cited by this paper
• Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma

  2002cited by this paper
• Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin

  2001cited by this paper

• Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven 7-Gene Stemness Signature that Predicts Progression

  2024cites this paper
• Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression

  2024cites this paper
• Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy

  2021cites this paper
• Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play

  2019cites this paper